These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 15700308)

  • 1. RASSF1A is not appropriate as an early detection marker or a prognostic marker for non-small cell lung cancer.
    Choi N; Son DS; Song I; Lee HS; Lim YS; Song MS; Lim DS; Lee J; Kim H; Kim J
    Int J Cancer; 2005 Jul; 115(4):575-81. PubMed ID: 15700308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
    Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
    Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of RASSF1A and p63 with poor recurrence-free survival in node-negative stage I-II non-small cell lung cancer.
    Ko E; Lee BB; Kim Y; Lee EJ; Cho EY; Han J; Shim YM; Park J; Kim DH
    Clin Cancer Res; 2013 Mar; 19(5):1204-12. PubMed ID: 23319821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of DAPK and RASSF1A promoter hypermethylation in non-small cell lung cancer (NSCLC).
    Niklinska W; Naumnik W; Sulewska A; Kozłowski M; Pankiewicz W; Milewski R
    Folia Histochem Cytobiol; 2009; 47(2):275-80. PubMed ID: 19926549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypermethylation of RASSF1A promoter is associated with the age at starting smoking and a poor prognosis in primary non-small cell lung cancer.
    Kim DH; Kim JS; Ji YI; Shim YM; Kim H; Han J; Park J
    Cancer Res; 2003 Jul; 63(13):3743-6. PubMed ID: 12839968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma.
    Tomizawa Y; Kohno T; Kondo H; Otsuka A; Nishioka M; Niki T; Yamada T; Maeshima A; Yoshimura K; Saito R; Minna JD; Yokota J
    Clin Cancer Res; 2002 Jul; 8(7):2362-8. PubMed ID: 12114441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer.
    Kim JS; Chae Y; Ha YS; Kim IY; Byun SS; Yun SJ; Kim WJ
    Clin Genitourin Cancer; 2012 Jun; 10(2):114-20. PubMed ID: 22382007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Analysis of RASSF1A promoter hypermethylation in serum DNA of non-small cell lung cancer].
    Yu ZH; Wang YC; Chen LB; Song Y; Liu C; Xia XY; Lin Q; Ma CY
    Zhonghua Zhong Liu Za Zhi; 2008 Apr; 30(4):284-7. PubMed ID: 18788633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypermethylation of RASSF1A and BLU tumor suppressor genes in non-small cell lung cancer: implications for tobacco smoking during adolescence.
    Marsit CJ; Kim DH; Liu M; Hinds PW; Wiencke JK; Nelson HH; Kelsey KT
    Int J Cancer; 2005 Mar; 114(2):219-23. PubMed ID: 15540210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer.
    Zhang Y; Wang R; Song H; Huang G; Yi J; Zheng Y; Wang J; Chen L
    Cancer Lett; 2011 Apr; 303(1):21-8. PubMed ID: 21255913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic role of APC and RASSF1A promoter methylation status in cell free circulating DNA of operable gastric cancer patients.
    Balgkouranidou I; Matthaios D; Karayiannakis A; Bolanaki H; Michailidis P; Xenidis N; Amarantidis K; Chelis L; Trypsianis G; Chatzaki E; Lianidou ES; Kakolyris S
    Mutat Res; 2015 Aug; 778():46-51. PubMed ID: 26073472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival.
    Brabender J; Usadel H; Danenberg KD; Metzger R; Schneider PM; Lord RV; Wickramasinghe K; Lum CE; Park J; Salonga D; Singer J; Sidransky D; Hölscher AH; Meltzer SJ; Danenberg PV
    Oncogene; 2001 Jun; 20(27):3528-32. PubMed ID: 11429699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aberrant methylation of RASGRF2 and RASSF1A in human non-small cell lung cancer.
    Chen H; Suzuki M; Nakamura Y; Ohira M; Ando S; Iida T; Nakajima T; Nakagawara A; Kimura H
    Oncol Rep; 2006 May; 15(5):1281-5. PubMed ID: 16596198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of Delta DNMT3B variants and its association with promoter methylation of p16 and RASSF1A in primary non-small cell lung cancer.
    Wang J; Walsh G; Liu DD; Lee JJ; Mao L
    Cancer Res; 2006 Sep; 66(17):8361-6. PubMed ID: 16951144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative promoter hypermethylation analysis of RASSF1A in lung cancer: comparison with methylation-specific PCR technique and clinical significance.
    Lee SM; Lee WK; Kim DS; Park JY
    Mol Med Rep; 2012 Jan; 5(1):239-44. PubMed ID: 21971684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA methylation markers and early recurrence in stage I lung cancer.
    Brock MV; Hooker CM; Ota-Machida E; Han Y; Guo M; Ames S; Glöckner S; Piantadosi S; Gabrielson E; Pridham G; Pelosky K; Belinsky SA; Yang SC; Baylin SB; Herman JG
    N Engl J Med; 2008 Mar; 358(11):1118-28. PubMed ID: 18337602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypermethylation of FHIT as a prognostic marker in nonsmall cell lung carcinoma.
    Maruyama R; Sugio K; Yoshino I; Maehara Y; Gazdar AF
    Cancer; 2004 Apr; 100(7):1472-7. PubMed ID: 15042681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients.
    Honorio S; Agathanggelou A; Schuermann M; Pankow W; Viacava P; Maher ER; Latif F
    Oncogene; 2003 Jan; 22(1):147-50. PubMed ID: 12527916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological significance of aberrant methylation of RARbeta2 at 3p24, RASSF1A at 3p21.3, and FHIT at 3p14.2 in patients with non-small cell lung cancer.
    Tomizawa Y; Iijima H; Nomoto T; Iwasaki Y; Otani Y; Tsuchiya S; Saito R; Dobashi K; Nakajima T; Mori M
    Lung Cancer; 2004 Dec; 46(3):305-12. PubMed ID: 15541815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypermethylation-modulated downregulation of RASSF1A expression is associated with the progression of esophageal cancer.
    Mao WM; Li P; Zheng QQ; Wang CC; Ge MH; Hu FJ; Fang XH; Dong ZM; Ling ZQ
    Arch Med Res; 2011 Apr; 42(3):182-8. PubMed ID: 21722812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.